Data from a post-hoc analysis of the phase 2b RESPOND trial (NCT04948151) showed no significant impact of age, race, or hormonal contraceptive use on the efficacy of topical sildenafil cream, 3.6%, ...

If successful, Sildenafil Cream could become the first FDA-approved treatment for FSAD, addressing a significant unmet need in women's sexual health. The company plans to submit the study protocol ...

We are excited about the potential for Daré’s Sildenafil Cream formulation to address this critical unmet need in women's sexual health, and that there is a clear path forward on how to ...

DARE Dare Bioscience Inc Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) ...

Detailed price information for Dare Bioscience Inc (DARE-Q) from The Globe and Mail including charting and trades.

FSAD is clinically analogous to erectile dysfunction in men. To date, there are no FDA-approved pharmacological treatments for FSAD; Daré's Sildenafil Cream has the potential to receive the first FDA ...

We are excited about the potential for Daré's Sildenafil Cream formulation to address this critical unmet need in women's sexual health, and that there is a clear path forward on how to evaluate ...